Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06615050 · ClinicalTrials.gov registry record · Phase 3
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
A Phase 3 study of Graft-versus-host Disease (GVHD), sponsored by Incyte Corporation.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 572
- Enrollment target
- 20
- Study locations
NCT06615050 is a Phase 3 study of Graft-versus-host Disease (GVHD) that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 572 participants, above the 205-participant average among 3 other Graft-versus-host Disease (GVHD) trials with a reported enrollment target (179% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT06615050, a Phase 3 study of Graft-versus-host Disease (GVHD), is actively recruiting participants, sponsored by Incyte Corporation.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 572 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Methotrexate (MTX)
- DRUG Tacrolimus (Tac)
- DRUG Ruxolitinib (Rux)
- DRUG Mycophenolate mofetil (MMF)
Study Locations (20)
Michigan
- University of Michigan - Ann Arbor
- Karmanos Cancer Institute - Detroit
- Henry Ford Hospital - Detroit
North Carolina
- University of North Carolina At Chapel Hill - Chapel Hill
- Levine Cancer Institute - Charlotte
- Duke University Medical Center - Durham
California
- Stanford Cancer Center - Palo Alto
- University of California San Francisco - San Francisco
Florida
- University of Miami - Miami
- Moffitt Cancer Center - Tampa
New York
- Mount Sinai Hospital - New York
- Memorial Sloan Kettering - New York
Ohio
- Cleveland Clinic - Cleveland
- Ohio State University - Columbus
Georgia
- Blood and Marrow Transplant Group of Georgia - Atlanta
Indiana
- Indiana University Cancer Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 572 participants |
| Start Date | 2025-04-02 |
| Est. Completion | 2031-01-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06615050
The ClinicalTrials.gov registry entry for NCT06615050 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 572 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 205-participant average among 3 other Graft-versus-host Disease (GVHD) trials with a reported enrollment target (179% higher). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Graft-versus-host Disease (GVHD) appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT06615050 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Michigan, North Carolina, California.
Frequently Asked Questions
What is clinical trial NCT06615050 about?
NCT06615050 is a clinical study titled "A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)". The purpose of this study is to assess Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation
What is the current status of trial NCT06615050?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 572 participants. The study started on 2025-04-02. Estimated completion is 2031-01-17.
What conditions does trial NCT06615050 study?
This clinical trial studies the following conditions: Graft-versus-host Disease (GVHD).
What interventions are being tested in trial NCT06615050?
The interventions under investigation include: Cyclophosphamide (DRUG), Methotrexate (MTX) (DRUG), Tacrolimus (Tac) (DRUG), Ruxolitinib (Rux) (DRUG), Mycophenolate mofetil (MMF) (DRUG).
Who is sponsoring clinical trial NCT06615050?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06615050 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Indiana, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Graft-versus-host Disease (GVHD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease
COMPLETED · Phase 3
-
Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation
RECRUITING · Phase 2
-
Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.